Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Titel:
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Auteur:
Bang, Yung-Jue Kang, Yoon-Koo Catenacci, Daniel V. Muro, Kei Fuchs, Charles S. Geva, Ravit Hara, Hiroki Golan, Talia Garrido, Marcelo Jalal, Shadia I. Borg, Christophe Doi, Toshihiko Yoon, Harry H. Savage, Mary J. Wang, Jiangdian Dalal, Rita P. Shah, Sukrut Wainberg, Zev A. Chung, Hyun Cheol